insights_auto
Nega LYEL oshdi 2,50%?
Batafsil oʻrganishchevron_right
LYEL:NASDAQ
Lyell Immunopharma Inc
8,19 US$
arrow_upward
+2,50%(+0,20) 1K
8,19 US$
0,00% (0,00)
bedtimeYopilgandan keyin
Savdolar yopilgan: 15-okt, 16:00:01 (GMT-4) · USD
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoLYEL tikeri uchun statistika yaratilmoqda...
Ochish
8,00 US$
Yuqori
8,44 US$
Past
7,76 US$
Bozor kapitali
200,70 mln
Oʻrtacha hajm
149,51 ming
Hajmi
0,00
52 haftalik eng yuqori
45,00 US$
52 haftalik eng past
7,32 US$
Aksiya boʻyicha daromad
-12,01 US$
Beta
-0,03
Muomaladagi aksiyalar
24,50 mln
Xodimlar soni
161
Ochish
8,00 US$
Yuqori
8,44 US$
Past
7,76 US$
Bozor kapitali
200,70 mln
Oʻrtacha hajm
149,51 ming
Hajmi
0,00
52 haftalik eng yuqori
45,00 US$
52 haftalik eng past
7,32 US$
Aksiya boʻyicha daromad
-12,01 US$
Beta
-0,03
Muomaladagi aksiyalar
24,50 mln
Xodimlar soni
161
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
ad-hoc-news.de
·
5 soat oldin
Lyell Immunopharma CMO sells 422 shares: USD 40.86 target for Lyell Immunopharma stock
Profil
Lyell Immunopharma, Inc. is an American clinical-stage biopharmaceutical company headquartered in San Francisco, California. Founded in 2018, the company develops next-generation cell therapies, including CAR T cell, using technologies intended to improve T-cell persistence, function, and resistance to exhaustion. Its pipeline includes therapies being developed for hematologic malignancies and solid tumors. Wikipedia
Lyell Immunopharma Inc haqida
CEO-
Xodimlar soni161
Asos solingan2018
Bosh ofislarSouth San Francisco, Kaliforniya, Amerika Qo‘shma Shtatlari
Sektor-
Veb-saytlyell.com